Featured Research

from universities, journals, and other organizations

New Radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma

Date:
May 14, 2002
Source:
Mayo Clinic
Summary:
A Mayo Clinic study indicates the first of a new class of drugs involving radioimmunotherapy benefited a significant number of patients with low-grade B cell non-Hodgkin’s lymphoma who have exhausted treatment options.

ROCHESTER, MINN. -- A Mayo Clinic study indicates the first of a new class of drugs involving radioimmunotherapy benefited a significant number of patients with low-grade B cell non-Hodgkin’s lymphoma who have exhausted treatment options.

Related Articles


The study, published in the May 15, 2002, issue of Journal of Clinical Oncology, investigated the ability of the drug Zevalin to hone in on and kill off the non-Hodgkin’s lymphoma B cells. Zevalin is the first radioimmunotherapy drug developed specifically to fight this common but usually fatal cancer of the lymph glands that, for unknown reasons, is on the increase in the United States. About 56,000 people are diagnosed with this cancer annually.

The randomized study involved 143 patients with B cell non-Hodgkin’s lymphoma who had previously failed the standard chemotherapy treatments. The study found that 80 percent of patients who received Zevalin experienced a positive response in that their tumor shrunk. That compared to a 56 percent response rate in patients receiving only Rituxan, another drug used to treat the cancer.

Most noteworthy, 30 percent of the patients receiving Zevalin achieved complete remission with no evidence of the cancer present, compared to only 16 percent of patients taking Rituxan.

Radioimmunotherapy combines monoclonal antibodies, which are antibodies produced in a laboratory to react against a cancer cell, with the ability of radiation to kill off cancer cells. The mixture of radiation and antibodies is given intravenously and travels through the bloodstream to the cancer cells.

“Unlike chemotherapy which goes through the whole body, Zevalin carries the radiation payload directly to the tumor,” says Thomas Witzig, M.D., a Mayo Clinic hematologist. “The drug radiates only about a five millimeter area around the tumor.”

Along with its ability to hone in on cancer cells, the drug is easier on patients physically.

“One treatment is required on an outpatient basis, compared to a series of treatments with chemotherapy that can last four to six months and sometimes include hospitalization because of serious side effects,” says Dr. Witzig. “There’s no hair loss or prolonged fatigue, nausea or vomiting. The most significant side effect is a temporary decrease in the blood count.”

Dr. Witzig and Gregory Wiseman, M.D., a Mayo Clinic nuclear medicine specialist, led the phase III research study. This study was one of several clinical trials on the drug conducted by Mayo Clinic and nine other cancer centers in the United States. The cumulative results led to the recent approval of Zevalin by the Food and Drug Administration for treatment of patients with relapsed B cell non-Hodgkin’s lymphoma.

Non-Hodgkin’s lymphoma ranks as the fifth most common type of cancer diagnosed in the United States. However, while incidences of most cancers have been decreasing in the past couple of decades, the number of patients diagnosed with non-Hodgkin’s lymphoma has been steadily increasing.

An estimated 300,000 Americans are currently living with the disease. Most of the patients are age 40 and older. In patients aged 60 years and older, the incidence of non-Hodgkin’s lymphoma is about 100 patients per 100,000 people. Zevalin is manufactured by IDEC Pharmaceuticals Corporation.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "New Radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma." ScienceDaily. ScienceDaily, 14 May 2002. <www.sciencedaily.com/releases/2002/05/020514074113.htm>.
Mayo Clinic. (2002, May 14). New Radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2002/05/020514074113.htm
Mayo Clinic. "New Radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma." ScienceDaily. www.sciencedaily.com/releases/2002/05/020514074113.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins